Best mRNA / LNP CDMOs in Europe

· updated as new inspection, certificate, and trial data enters the platform
← All mRNA/LNP CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China
17
CDMOs tracked
17
Fully scored
7
With FDA records
29
FDA inspections
129
EMA/MHRA GMP certs
2
Warning letters

For European-manufactured mrna / lnp programs, BioNTech (Mfg Services), Merck KGaA / MilliporeSigma (CDMO), and Lonza lead CDMO Signal's ranking of mrna / lnp CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 35 scored mrna / lnp CDMOs to 4 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.

Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 4 NAI (no action), 22 VAI (voluntary action), 3 OAI (official action). Leading inspection & GMP sites: Germany (37), United States (25), Italy (23), UNITED KINGDOM (20), Denmark (17).

Last updated 2026-09-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
BNT
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
 84.9 100.0 0 insp · 8 GMP — 28 programs
2
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
 81.8 98.7 2 insp · 2 GMP — 22 programs
3
Lonza
Basel, Switzerland
 76.0 95.7 2 insp · 8 GMP — 1 programs
4
CVC
CureVac (CDMO Services)
Tubingen, DE
 75.3 100.0 0 insp · 7 GMP — 4 programs
5
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
 88.0 100.0 0 insp · 3 GMP — 0 programs
6
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
 84.8 100.0 0 insp · 23 GMP Expanding 0 programs
7
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
 81.6 100.0 0 insp · 13 GMP — 0 programs
8
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
 81.1 98.9 4 insp · 10 GMP — 0 programs
9
KE
Kaneka Eurogentec
Seraing, BE
 80.3 100.0 0 insp · 4 GMP — 0 programs
10
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
 74.0 — — — 0 programs
11
Catalent
Bagsværd, Denmark (operating under Novo Holdings; key US DP site: Bloomington, IN)
 73.1 74.9 12 insp · 37 GMP — 0 programs
12
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
 73.1 74.9 1 insp · 0 GMP Available 0 programs
13
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
 73.0 95.7 1 insp · 0 GMP Limited 0 programs
14
BP
BSP Pharmaceuticals
Latina, Italy
 70.5 83.6 7 insp · 14 GMP — 0 programs
15
HP
HIPRA Biotech Services
Amer, Spain
 63.0 — — — 0 programs
16
QB
Quantoom Biosciences
Gosselies, BE
 56.5 — — — 0 programs
17
EH
Ethris
Planegg, DE
 56.5 — — — 0 programs
How we score CDMOs →

What to evaluate in a mRNA / LNP CDMO

IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

mRNA / LNP CDMOs — Frequently Asked Questions

Who are the top mRNA / LNP CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked mRNA / LNP CDMOs include BioNTech (Mfg Services), Merck KGaA / MilliporeSigma (CDMO), Lonza. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many mRNA / LNP CDMOs have FDA inspection records?
CDMO Signal tracks 7 mRNA / LNP CDMOs with FDA inspection records and 129 EMA/MHRA GMP certificates across the group.
What should I look for in an mRNA / LNP CDMO?
Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.
Do mRNA CDMOs also make the LNP and plasmid?
Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.
Related modalities
Plasmid DNA CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector